lab printout with repeated pixels became the thread
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
lab printout with repeated pixels became the thread
-
ナレーター：
-
著者：
The discovery that two western blot images were pixel-for-pixel identical - not similar, identical - triggered an unraveling that touched $16,000,000 in federal grants and sent hundreds of Alzheimer's patients into clinical trials. How could a microscopic flaw in image backgrounds help propel a drug to human trials, and what exactly remains unknown about the science behind it?
In this episode, we tell the sequence of events that followed that matched background pixels: the history of the academic collaboration, the drug candidate simufilam, the federal funding and clinical trials, and the unresolved questions left by conflicting expert opinions. How did a single laboratory's findings become the foundation for a treatment that showed no biomarker benefit in a phase IIb study?
Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Pain Therapeutics (later Cassava Sciences)
Compound: PTI-125 (simufilam)
Finding: phase IIb biomarker results failed two months after first patient dosing in March 2020
- The identical western blot pixels were detected in images that were supposed to represent different experiments on different days.
- $16,000,000 in federal grants were implicated as unraveling after the image discovery.
- Hundreds of Alzheimer's patients were enrolled in clinical trials of simufilam following the published research.
- All evidence supporting the filamin A - amyloid beta 42 mechanism came from Wang's laboratory at CUNY, with no independent replication reported.
- The phase IIb biomarker study reported results that did not show the expected biological improvement two months after dosing began in March 2020.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません